Mitochondrial Research · Cardioprotection & Ageing

SS-31 Peptide (Elamipretide): Mitochondrial Research Overview for UK Laboratories

Topics covered: Mechanism of mitochondrial targeting · Cardiolipin interaction · Cardioprotection research · Skeletal muscle and ageing models · Renal ischaemia models · Protocol design and reconstitution

SS-31 (also known as Elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide that belongs to the Szeto-Schiller (SS) family of mitochondria-targeted peptides developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College. Unlike most research peptides that act through cell surface receptors, SS-31 has a unique mechanism: it selectively concentrates in the inner mitochondrial membrane, where it interacts with cardiolipin — a phospholipid that is essential for the structural integrity and functional efficiency of the mitochondrial electron transport chain.

SS-31 has become one of the most studied mitochondria-targeted compounds in preclinical research, with published studies spanning cardioprotection, skeletal muscle function, renal ischaemia-reperfusion injury, neurodegeneration, and ageing biology. Its unique mechanism — targeting the inner mitochondrial membrane rather than acting through a cell surface receptor — makes it a valuable research tool for studies where mitochondrial dysfunction is a central hypothesis.

1. Structure and Mechanism of Mitochondrial Targeting

SS-31 has the sequence D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2′,6′-dimethyltyrosine — a non-natural amino acid that contributes to the compound’s antioxidant properties and its interaction with cardiolipin. The molecular weight of SS-31 is 639.8 Da. Its net charge is +3 at physiological pH, which is a key feature of its mitochondrial targeting mechanism.

The mitochondrial inner membrane has a large negative membrane potential (approximately −180 mV), which is maintained by the proton gradient generated by the electron transport chain. This electrochemical gradient drives the selective accumulation of positively charged molecules in the mitochondrial matrix and inner membrane. SS-31’s +3 charge causes it to accumulate in the inner mitochondrial membrane at concentrations estimated to be 1,000-fold higher than the extracellular concentration — a passive targeting mechanism that does not require active transport or specific receptor binding.

Once concentrated in the inner mitochondrial membrane, SS-31 interacts specifically with cardiolipin through electrostatic and hydrophobic interactions. This interaction is the basis for its effects on mitochondrial function.

2. Cardiolipin Interaction: The Central Mechanism

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane, where it constitutes approximately 20% of the total lipid content. It plays critical structural and functional roles in mitochondrial biology: it stabilises the electron transport chain complexes (particularly Complex I, III, and IV) and their supercomplexes (respirasomes); it is required for the structural integrity of the cristae (the folded inner membrane structures where ATP synthesis occurs); and it is a co-factor for cytochrome c in the electron transport chain.

In conditions of oxidative stress, ischaemia, or mitochondrial dysfunction, cardiolipin undergoes peroxidation — oxidative damage to its polyunsaturated fatty acid chains. Cardiolipin peroxidation disrupts the electron transport chain, reduces ATP synthesis efficiency, promotes cytochrome c release (a trigger for apoptosis), and contributes to the generation of reactive oxygen species (ROS) in a self-amplifying cycle.

SS-31’s interaction with cardiolipin has two demonstrated effects: it stabilises cardiolipin’s interaction with cytochrome c, preventing the conversion of cytochrome c from an electron carrier to a peroxidase (which occurs when cytochrome c binds to peroxidised cardiolipin); and it reduces cardiolipin peroxidation by scavenging ROS in the immediate vicinity of the inner mitochondrial membrane. Both effects contribute to the preservation of electron transport chain function and the prevention of apoptosis in conditions of mitochondrial stress.

3. Cardioprotection Research

Cardioprotection is the most extensively studied application of SS-31 in preclinical research. The cardiac muscle is one of the most mitochondria-dense tissues in the body — cardiomyocytes contain approximately 5,000 mitochondria per cell, occupying about 30% of cell volume — making it particularly sensitive to mitochondrial dysfunction.

In ischaemia-reperfusion injury models (where blood flow is temporarily interrupted and then restored, mimicking myocardial infarction), SS-31 has consistently demonstrated reductions in infarct size, preservation of cardiac function (measured by echocardiography or haemodynamic monitoring), and reduction in cardiomyocyte apoptosis. These effects are observed when SS-31 is administered before ischaemia (pre-treatment), during reperfusion (treatment at the time of reperfusion), and in some studies, after reperfusion (post-treatment) — though pre-treatment and reperfusion-time administration generally produce the largest effects.

SS-31 has also been studied in models of heart failure, where chronic mitochondrial dysfunction contributes to progressive cardiac remodelling and contractile dysfunction. In these models, SS-31 has demonstrated improvements in cardiac energetics (ATP production efficiency), reduction in mitochondrial ROS generation, and attenuation of cardiac fibrosis and hypertrophy.

4. Skeletal Muscle and Ageing Models

Mitochondrial dysfunction is a central feature of age-related skeletal muscle decline (sarcopenia). Aged skeletal muscle shows reduced mitochondrial content, impaired electron transport chain function, increased mitochondrial ROS generation, and reduced ATP synthesis capacity — all of which contribute to reduced muscle force generation and fatigue resistance. SS-31 has been studied in aged rodent models as a tool to investigate whether mitochondrial-targeted intervention can reverse or attenuate these age-related changes.

In aged mouse models, SS-31 administration has been shown to improve mitochondrial morphology (reducing the fragmented, swollen mitochondria characteristic of aged muscle), increase ATP synthesis capacity, reduce mitochondrial ROS production, and improve skeletal muscle force generation and fatigue resistance. These effects are observed after both acute and chronic administration, suggesting that the compound can produce rapid improvements in mitochondrial function as well as longer-term structural changes.

SS-31 has also been studied in models of disuse atrophy (muscle wasting due to immobilisation or denervation), where mitochondrial dysfunction contributes to the atrophic response. In these models, SS-31 attenuates muscle mass loss and preserves mitochondrial function during the atrophy period.

5. Renal Ischaemia-Reperfusion Models

The kidney is the second most mitochondria-dense organ after the heart, and renal tubular cells are highly dependent on oxidative phosphorylation for ATP production. Renal ischaemia-reperfusion injury — a common cause of acute kidney injury in clinical settings — involves mitochondrial dysfunction as a central pathological mechanism. SS-31 has been studied extensively in renal ischaemia-reperfusion models, where it has demonstrated reductions in tubular cell apoptosis, preservation of renal function (measured by serum creatinine and BUN), and attenuation of histological injury.

The renal ischaemia-reperfusion model is one of the most commonly used models for SS-31 research because the kidney’s high mitochondrial density makes it particularly sensitive to mitochondrial-targeted interventions, and because the endpoints (serum creatinine, BUN, histology) are well-established and reproducible.

6. Research Applications Summary

7. Protocol Design and Reconstitution

Reconstitution

SS-31 dissolves readily in bacteriostatic water or sterile saline. Recommended reconstitution: add 1 mL bacteriostatic water to the 5 mg vial = 5 mg/mL stock solution. The solution should be clear and colourless. SS-31 is stable in aqueous solution at 2–8°C for up to 28 days with bacteriostatic water. For long-term storage, aliquot and freeze at −20°C.

Dosing in In Vivo Models

Published preclinical studies use a wide range of SS-31 doses depending on the model and endpoint. Common dose ranges in rodent studies: 0.05–5 mg/kg for acute cardioprotection studies; 1–3 mg/kg/day for chronic skeletal muscle and ageing studies; 0.5–2 mg/kg for renal ischaemia-reperfusion studies. Administration routes used in published studies include subcutaneous, intraperitoneal, and intravenous — the choice depends on the study design and the timing requirements relative to the ischaemic insult.

In Vitro Dosing

For in vitro studies using isolated mitochondria or cell lines, SS-31 is typically used at concentrations of 10 nM–10 µM. The compound is added directly to the incubation medium. For Seahorse XF assays (measuring oxygen consumption rate and extracellular acidification rate), SS-31 is typically injected at concentrations of 100 nM–1 µM during the assay to observe acute effects on mitochondrial respiration.

Related Guides & Resources